Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2013

View Archived Issues

Correlation of a serum biomarker with disease severity in patients with sarcoidosis

AZD-0914 shows potential against N. gonorrhoeae and S. aureus

Phase I/II study of acne candidate DRM-01B under way

Vascular endothelial growth factors linked to severity of hypersensitivity pneumonitis

Cancer Research Technology and Teva Pharmaceutical form alliance for cancer drugs

Affimed Therapeutics and the Leukemia & Lymphoma Society partner to advance AFM-13

Servier forms license agreement with SIMM for lucitanib in China

Novel PDE10A inhibitors described by Lundbeck

First muscarinic acetylcholine M5 receptor NAM discovered

ISA initiates phase I/II trial in HIV-positive men with HPV16-positive AIN

Constellation Pharmaceuticals begins phase I CPI-0610 study in lymphoma

arGEN-X files CTA for first-in-man ARGX-111 cancer study

Lyxumia launched in Japan

FDA grants orphan drug designation to Soligenix's SGX-94

Cancer vaccine KRM-20 evaluated in phase I prostate cancer trial

Volasertib receives FDA breakthrough therapy designation for AML

Provenge obtains European approval

Chiesi Farmaceutici to acquire total ownership of Cornerstone Therapeutics

FDA clears Quidel molecular diagnostic tests for use on QuantStudio Dx

Sorrento Therapeutics-IgDraSol merger complete

Novartis designs novel PI3K inhibitors for cancer

Encode Bio patents NEMO binding domain fusion proteins

SK Chemicals discloses novel GnRH receptor antagonists

Phase III trials of ATX-101 for reducing submental fat meet endpoints

Dolutegravir designated as orphan drug in Japan

FDA accepts for review Epanova NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.